FI940681A0 - Menetelmä ja koostumuksia, jotka liittyvät Moraxella catarrhalisin käyttökelpoisiin antigeeneihin - Google Patents

Menetelmä ja koostumuksia, jotka liittyvät Moraxella catarrhalisin käyttökelpoisiin antigeeneihin

Info

Publication number
FI940681A0
FI940681A0 FI940681A FI940681A FI940681A0 FI 940681 A0 FI940681 A0 FI 940681A0 FI 940681 A FI940681 A FI 940681A FI 940681 A FI940681 A FI 940681A FI 940681 A0 FI940681 A0 FI 940681A0
Authority
FI
Finland
Prior art keywords
moraxella catarrhalis
omps
proteins
methods
variants
Prior art date
Application number
FI940681A
Other languages
English (en)
Swedish (sv)
Other versions
FI106844B (fi
FI940681A (fi
Inventor
Eric J Hansen
Merja Helminen
Isobel Maciver
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of FI940681A0 publication Critical patent/FI940681A0/fi
Publication of FI940681A publication Critical patent/FI940681A/fi
Application granted granted Critical
Publication of FI106844B publication Critical patent/FI106844B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI940681A 1991-08-15 1994-02-14 Menetelmä Moraxella catarrhalisin antigeeneihin liittyvien koostumusten ja vasta-aineiden valmistamiseksi sekä DNA-segmentti, yhdistelmävektori ja yhdistelmäisäntäsolu FI106844B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/745,591 US5552146A (en) 1991-08-15 1991-08-15 Methods and compositions relating to useful antigens of Moraxella catarrhalis
US74559191 1991-08-15
US9206869 1992-08-14
PCT/US1992/006869 WO1993003761A1 (en) 1991-08-15 1992-08-14 METHODS AND COMPOSITIONS RELATING TO USEFUL ANTIGENS OF $i(MORAXELLA CATARRHALIS)

Publications (3)

Publication Number Publication Date
FI940681A0 true FI940681A0 (fi) 1994-02-14
FI940681A FI940681A (fi) 1994-04-07
FI106844B FI106844B (fi) 2001-04-30

Family

ID=24997358

Family Applications (1)

Application Number Title Priority Date Filing Date
FI940681A FI106844B (fi) 1991-08-15 1994-02-14 Menetelmä Moraxella catarrhalisin antigeeneihin liittyvien koostumusten ja vasta-aineiden valmistamiseksi sekä DNA-segmentti, yhdistelmävektori ja yhdistelmäisäntäsolu

Country Status (14)

Country Link
US (3) US5552146A (fi)
EP (1) EP0612250B1 (fi)
JP (1) JP3499868B2 (fi)
KR (1) KR100271888B1 (fi)
AT (1) ATE140627T1 (fi)
AU (1) AU666329B2 (fi)
CA (1) CA2115565C (fi)
DE (1) DE69212495T2 (fi)
DK (1) DK0612250T3 (fi)
ES (1) ES2092696T3 (fi)
FI (1) FI106844B (fi)
GR (1) GR3021423T3 (fi)
NO (2) NO308413B1 (fi)
WO (1) WO1993003761A1 (fi)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693654B1 (fr) * 1992-07-20 1994-08-26 Oreal Médicament, notamment immunomodulateur, contenant des enveloppes ou fractions d'enveloppes de bactéries filamenteuses non photosynthétiques et non fructifiantes, et sa préparation.
EP0624376B1 (en) * 1993-05-13 2000-03-15 American Cyanamid Company Preparation and uses of LOS-depleted outer membrane proteins of gram-negative cocci
US5712118A (en) * 1993-09-29 1998-01-27 Research Foundation Of State University Of New York Vaccine for branhamella catarrhalis
US5607846A (en) * 1994-05-17 1997-03-04 Research Foundation Of State University Of New York Vaccine for moraxella catarrhalis
US6121427A (en) * 1994-10-24 2000-09-19 Connaught Laboratories Limited Major outer membrane protein CD of branhamella
US6440425B1 (en) * 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6335018B1 (en) * 1995-05-01 2002-01-01 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
KR100500000B1 (ko) * 1996-05-03 2005-12-12 안텍스 바이오로직스 인코퍼레이션 모락셀라카타르할리스외측막단백질-16폴리펩티드,이의유전자서열및이의용도
US7341727B1 (en) * 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
US6004562A (en) * 1996-08-16 1999-12-21 The Research Foundation Of The State University Of New York Outer membrane protein B1 of Moraxella catarrhalis
US6558677B2 (en) * 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
CA2274495C (en) 1996-12-20 2009-06-02 Board Of Regents, The University Of Texas System Uspa1 and uspa2 antigens of moraxella catarrhalis
GB9810084D0 (en) 1998-05-11 1998-07-08 Cortecs Uk Ltd Proteins
AU4260099A (en) * 1998-05-12 1999-11-29 Smithkline Beecham Biologicals (Sa) Compounds from moraxella catarrhalis
GB9810285D0 (en) * 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
GB9812440D0 (en) * 1998-06-09 1998-08-05 Smithkline Beecham Biolog Novel compounds
CZ303653B6 (cs) 1999-03-19 2013-01-30 Smithkline Beecham Biologicals S. A. Imunogenní prostredek
GB9914945D0 (en) * 1999-06-25 1999-08-25 Smithkline Beecham Biolog Novel compounds
GB9921691D0 (en) * 1999-09-14 1999-11-17 Smithkline Beecham Sa Novel compounds
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
KR101239242B1 (ko) 2002-08-02 2013-03-11 글락소스미스클라인 바이오로지칼즈 에스.에이. 항원 조합물을 포함하는 나이세리아 백신 조성물
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
CN102716480B (zh) 2005-04-08 2023-03-21 惠氏有限责任公司 多价肺炎球菌多糖-蛋白质缀合物组合物
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
CA2808919C (en) 2005-12-22 2016-04-19 Glaxosmithkline Biologicals S.A. Streptococcus pneumoniae capsular saccharide vaccine
BRPI0707154B8 (pt) 2006-01-17 2022-12-20 Forsgren Arne composição de vacina
EP2687228B1 (en) 2007-06-26 2017-07-19 GlaxoSmithKline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
BRPI0913268A2 (pt) 2008-05-30 2016-03-15 U S A As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army vacina de vesícula de membrana externa nativa multivalente meningocócica, métodos de fabricação e uso da mesma
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
CN102869377A (zh) 2010-03-10 2013-01-09 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
IE87414B1 (en) 2017-05-30 2023-07-19 Glaxosmithkline Biologicals Sa Novel methods for manufacturing an adjuvant
BR112020010790A2 (pt) 2017-12-01 2020-11-10 Glaxosmithkline Biologicals S.A. purificação da saponina
WO2020030572A1 (en) 2018-08-07 2020-02-13 Glaxosmithkline Biologicals Sa Processes and vaccines
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
JP2022535091A (ja) 2019-06-05 2022-08-04 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030556A (en) * 1989-03-30 1991-07-09 Danielle Beaulieu Species-specific DNNA probe for the detection of Branhamella catarrhalis

Also Published As

Publication number Publication date
JPH07501210A (ja) 1995-02-09
DE69212495T2 (de) 1997-03-06
GR3021423T3 (en) 1997-01-31
US5759813A (en) 1998-06-02
KR100271888B1 (ko) 2000-11-15
CA2115565A1 (en) 1993-03-04
FI106844B (fi) 2001-04-30
JP3499868B2 (ja) 2004-02-23
NO20002413D0 (no) 2000-05-09
US5552146A (en) 1996-09-03
EP0612250B1 (en) 1996-07-24
DE69212495D1 (de) 1996-08-29
AU666329B2 (en) 1996-02-08
AU2487892A (en) 1993-03-16
ATE140627T1 (de) 1996-08-15
NO940502L (no) 1994-03-28
EP0612250A1 (en) 1994-08-31
NO20002413L (no) 2000-05-09
DK0612250T3 (da) 1996-11-25
ES2092696T3 (es) 1996-12-01
WO1993003761A1 (en) 1993-03-04
US5599693A (en) 1997-02-04
FI940681A (fi) 1994-04-07
NO308413B1 (no) 2000-09-11
NO940502D0 (no) 1994-02-14
CA2115565C (en) 2007-08-07

Similar Documents

Publication Publication Date Title
FI940681A (fi) Menetelmä ja koostumuksia, jotka liittyvät Moraxella catarrhalisin käyttökelpoisiin antigeeneihin
DE69229476T2 (de) Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe
NO976119D0 (no) OMP26-antigen fra Haemophilus influenzae
WO1998028333A3 (en) USPA1 AND USPA2 ANTIGENS OF $i(MORAXELLA CATARRHALIS)
ATE217196T1 (de) Impfstoff auf urease-basis gegen helicobacter infektionen
FI102382B1 (fi) Ilmentämisjärjestelmä ihmisen respiratory syncytial -viruksen glykoproteiinien immunogeenisia fragmentteja sisältäviä kimeerisiä glykoproteiineja varten
EP0090581A3 (en) Small peptides with the specificity of foot and mouth disease viral antigens
DK0461177T3 (da) Humant intra-acrosomalt spermantigen til anvendelse i en svangerskabsforebyggende vaccine
ATE183241T1 (de) Impstoff gegen streptococcus suis-infektion
FI924457A0 (fi) Kompositioner och behandlingsfoerfarande foer lunginflammation i djur
DK482788A (da) Vacciner mod og diagnostiske bestemmelser af haemophilus influenzae
YU12991A (sh) Rekombinantne vakcine protiv kokcidioze-5-7 eimeria površinski antigen
ATA171686A (de) Verfahren zur herstellung von gegen pseudomonas aeruginosa infektionen wirksamen praeparationen
FR2736064B1 (fr) Epitopes protecteurs de l'adenyl cyclase-hemolysine(ac-hty). leur application au traitement ou a la prevention des infections par bordetella
ATE154244T1 (de) Induzierung eines schutzes gegen virale infektionen
DE69119785D1 (de) Zweiphasensystem zur herstellung und präsentation von fremdantigenen in hybriden lebendimpfstoffen
FI902814A0 (fi) Proteiner, vaccin och nukleinsyror.
ATE103817T1 (de) Gegen pseudomonas aeruginosa-infektionen wirksame praeparationen sowie immunglobulin-g-haeltige, gegen bakterium pseudomonas aeruginosa wirksame praeparationen.
WO1996034884A3 (en) Synthetic peptides of m. gallisepticum, antibodies thereto, their preparation and use